ANT-GROUP
2.8.2022 11:16:03 CEST | Business Wire | Press release
Coty Inc. (NYSE: COTY) ("Coty"), one of the world’s leading beauty companies and global leaders in fragrance, has officially signed the Global Travel Retail Joint Business Partnership with Ant Group to enhance the cooperation in digitalization. The agreement means that Coty will be the first beauty company to reach the strategic partnership in travel retail to support digital platforms like Alipay and other digital payment methods at a global level through Alipay+, a suite of global cross-border mobile payments and marketing solutions operated by Ant Group.
Based on the partnership, Coty will continue expanding the travel retail business through the digital operation powered by Alipay+, by creating comprehensive and diversified brand campaigns via Alipay and other payment platforms, and offering more customized consumer experience with higher quality and efficiency. This strategic partnership will extend from China to a wider area of APAC, and furtherly to Coty’s global travel retail market.
In the past year, Coty's travel retail business saw an outstanding performance. The traffic and sales of brick & mortar retail stores in Hainan saw strong growth with the help of digital operation, and the duty-free business in China achieved a triple-digit growth.
Digital operation is a clear strategic focus for Coty Travel Retail to innovate online and offline shopping experiences with a traveler-centric approach. Alipay, as a leading digital open platform leveraged by over 80 million businesses serving more than 1 billion consumers, is a valuable partner of Coty to co-create the future of beauty by innovative marketing capabilities and digital payment solutions. Since 2021, Coty has partnered with Alipay together on a series of travel retail activations, including Lancaster Super Brand Day, fragrance annual award, and had “Travel Around World” campaign debut in June.
"The cooperation with Ant Group in digitalization will help us serve our customers better," Caroline Andreotti, Executive Vice President of Coty's Global Travel Retail Business , remarked at the signing ceremony. "In the future, Coty and Ant will continue to work together to explore more possibilities of digital channels to improve consumer experience. We will also aim to deliver better services and products to more consumers around the world on their travel journey, and let them enjoy a better, more convenient and sustainable future."
With the signing of this agreement, Coty will go forward hand in hand with Ant Group to boost the development of digital service as well as the travel retail business, and will continue to develop more in-depth cooperation in an all-round way, across precision marketing, omni channel activations, and digital payment solution.
Coty's travel retail department is bringing the global iconic brands and tourists’ most favorable regional brands to travel retail channels, covering prestige and consumer brands, to build a matrix that include three product categories – fragrance, makeup, and skincare. At the present, the brands that Coty’s travel retail department is operating in Asia Pacific market include: 2-axis beauty brands (covering makeup and fragrance) -- Gucci beauty and Burberry beauty; the fragrance category -- Chloe, Tiffany, Miu Miu, Marc Jacobs, Calvin Klein; and the skincare category, of which, Lancaster, founded in Monaco in 1946, is a representative among the iconic high-end skincare brands.
The skincare category, in particular, has grown exponentially in Asia and represents a huge growth opportunity for Coty Travel Retail. By launching Lancaster with an Asia-focused product line-up, Coty targets to become an even stronger global player in skincare. It features new merchandising designs and offers the Asian consumers effective, sophisticated, safe, and sustainable personal care products customized to fit their regional needs. The key markets for this new product line-up are China, Korea, Thailand, and India focusing on the key markets for the category in the travel retail industry and a strategic vector of growth for the company .
Till now, Lancaster has set up four brick & mortar retail stores in Hainan and launched an official mini program on the Alipay platform, injecting a booster into the skincare business expansion of Coty in APAC.
With innovative technologies and solutions, Alipay+ brings an easy way to capture digital-first customers and makes it more convenient for merchants to serve hundreds of millions of users of leading digital payment service providers. Especially, through a one-stop integration and simple technical adaption, merchants can access all existing and later-onboarded digital payment methods brought by Alipay+. Moreover, Alipay+ can help merchants further extend the reach of potential users through its rich marketing campaign solutions.
Facing the impact and challenge caused by the COVID-19, Alipay+ has been working with brands since 2020, to find a way out for the travel retail industry in the post-pandemic era. With the comprehensive understanding of brand business, Alipay+ is making efforts to empower digital operation and transformation of business partners, and to improve consumers’ shopping experience with its payment and marketing solutions.
About Coty, Inc.
Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in more than 130 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and, we are committed to creating our own positive impact on the planet. Learn more at coty.com or on LinkedIn and Instagram.
About Ant Group and Alipay+
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, a suite of global cross-border mobile payments and marketing solutions which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005528/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom